See What HealthDay Can Do For You
Contact Us

Clinical Trials Update: July 3, 2007

Vascular Diseases Smoking Cessation Vaccines

(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:

Vascular Diseases

This study will evaluate the effectiveness and safety of treatment with Sutent in people with unresectable or metastatic vascular sarcoma. Patients may be eligible if treated previously with one or two chemotherapy regimens, bevacizumab, or tyrosine kinase inhibitors. Candidates must be 18 or older and have a histopathologically-proven diagnosis of angiosarcoma, epithelioid sarcoma-like hemangioendothelioma, or Kaposis sarcoma. Additional criteria apply.

The research site is in New York City.

More information

Please see http://www.centerwatch.com/patient/studies/cat302.html.

-----

Smoking Cessation

This seven-week outpatient study will evaluate an investigational medication to help people quit smoking. Participants must be ages 12 to 16, smoke at least three cigarettes a day, be physically healthy, and weigh at least 66 pounds.

The research site is in Houston, Texas.

More information

Please see http://www.centerwatch.com/patient/studies/cat237.html.

-----

Vaccines

This study will evaluate an investigational meningococcal vaccine. Participants must be ages 11 to 55 and in general good health. Research-related medical evaluations and study vaccine will be provided at no cost, and financial compensation is available for participation.

The research site is in Salt Lake City, Utah.

More information

Please see http://www.centerwatch.com/patient/studies/cat372.html.

-----

Copyright 2007 Thomson CenterWatch. All rights reserved.

Consumer News

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.